Physician profile
Summer Miller
NPI 1831829167
$6,007.31
in general payments reported to CMS, 2019-2025
17 companies · $2,099 in 2025
The $2,099 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $565 · 2023: $1,665 · 2024: $1,678 · 2025: $2,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,430 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,429.97 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $872.64 | 2023-2025 | |
| Alkermes, INC. | $665.79 | 2022-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $579.05 | 2022-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $578.16 | 2023-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Supernus Pharmaceuticals, INC. | $557.35 | 2022-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $448.34 | 2022-2025 | Invega Sustenna, Invega, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $396.03 | 2022-2025 | Caplyta |
| Tris Pharma INC | $375.88 | 2022-2025 | Dyanavel Xr, Onyda Xr |
| Lundbeck LLC | $361.81 | 2023-2025 | Abilify Asimtufii, Rexulti |
| Teva Pharmaceuticals USA, INC. | $313.01 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $244.28 | 2022-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $218.89 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $203.77 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $99.76 | 2022-2023 | Trintellix |
| Avanir Pharmaceuticals, INC. | $55.30 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $23.99 | 2024 | Perseris |
| Merck Sharp & Dohme LLC | $13.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Summer Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.